Background: This prospective, open-label, non-comparative, multicentre, long-term phase IV study is examining the efficacy and safety of somatropin [recombinant human growth hormone (rhGH)] in short children born small for gestational age (SGA) and its impact on the incidence of diabetes. This report is the first interim analysis of patients who have completed 1 year of treatment.
CITATION STYLE
Schwarz, H.-P., Birkholz-Walerzak, D., Szalecki, M., Walczak, M., Galesanu, C., Metreveli, D., … Schuck, E. (2014). One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age. Biologics in Therapy, 4(1–2), 1–13. https://doi.org/10.1007/s13554-014-0014-4
Mendeley helps you to discover research relevant for your work.